Announcements Trials
Browse Landscape

Phase

Phase 2 5

Status

Unknown 3Withdrawn 1Recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 5

Conditions

Carcinoma, Non-Small-Cell Lung 5Stomach Neoplasms 3Melanoma 2Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Locally Advanced Colorectal Cancer 1HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma 1Gastric Adenocarcinoma 1Colorectal Cancer Metastatic 1Breast Neoplasms 1Advanced Gastric Cancer 1

Interventions

Carboplatin 361Pemetrexed 276Cisplatin 230Paclitaxel 213Docetaxel 205Gemcitabine 160Erlotinib Hydrochloride 150Bevacizumab 132pembrolizumab 129Radiotherapy 114Nivolumab 88durvalumab 84Drug Therapy 84osimertinib 82atezolizumab 58Vinorelbine 53Gefitinib 53Radiosurgery 50Cetuximab 39Taxes 37130-nm albumin-bound paclitaxel 36Ipilimumab 34anlotinib 33Surgical Procedures, Operative 33Magnetic Resonance Spectroscopy 33Etoposide 30Albumin-Bound Paclitaxel 29tislelizumab 27icotinib 27aflutinib 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Non-Small-Cell Lung × SHR-1701 × Clear all
NCT07175220 2025-11-18

Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Recruiting
200 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04699968 2023-06-07

A Trial of SHR-1701 With or Without Famitinib in Patients With Advanced or Metastatic NSCLC

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04580498 2023-05-19

A Trial of SHR-1701 With or Without Chemotherapy in Patients With Stage III NSCLC

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Unknown
107 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05177497 2022-01-04

SHR-1701 for Consolidation Therapy After Concurrent Chemoradiotherapy in Inoperable Stage III NSCLC

Shanghai Chest Hospital

Phase 2 Unknown
19 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04560244 2020-09-23

A Trial of SHR1701 Combined With Radiotherapy for Metastatic Non-small Cell Lung Cancer Failure After First-line Treatment

Shandong Cancer Hospital and Institute

Phase 2 Unknown
15 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡